Man standing and pitching to a group of business people in conference room

Proven experience.
Practical innovation.

Our 350+ experts, including MDs, PharmDs, economists, epidemiologists, and seasoned commercial leaders, have supported more than 200 launches and 250 HTA and payor submissions globally. We operate with calm authority in high-stakes environments, bringing both strategic clarity and operational precision.

We do more than advise. We:

  • Turn scientific strategy, evidence, and medical communications into credible narratives that shape decisions​
  • Align evidence, pricing, and strategy to secure reimbursement and reduce access risk
  • Strengthen positioning through data-informed commercial strategy
  • Deliver rare disease and specialty market insights that reveals opportunity others miss
  • Activate agile field and engagement models that sustain long-term adoption
  • De-risk and accelerate momentum for a successful launch

Innovation, for us, is disciplined and outcome-driven. Bold enough to challenge assumptions. Grounded enough to execute.

Integrated expertise across the product lifecycle

We combine deep scientific rigor, commercial judgment, and disciplined execution under one accountable model. Our senior experts stay engaged from strategy through activation — connecting insights across medical, access, commercial, and patient functions to elevate performance.

Our integrated capabilities ⇓

What our clients are saying

The team is passionate about what they do and it really shows in their high-quality, creative solutions.

Senior VP, small biotech

The pricing and market access research was a high quality work project, which included detailed information to define the overall and country strategy while the gap analysis was instrumental in the next steps preparation.

Executive director, biotech

It was brilliantly smart and very well explained. It seems obvious now but that is what genius is, making complex things appear simple.

Associate director, mid-sized pharma

The strategic approach to problem solving is a breath of fresh air. We highly value their HTA consulting knowledge and expertise, and they consistently deliver the best solution for us.

Value demonstration & access lead, big pharma
Top down view of blue water flowing on sand

A partner built for the age of opportunity

In an environment defined by fragmented markets, rising evidence thresholds, regulatory uncertainty, and internal resource constraints, doing more of the same is not enough.

Acumetis integrates expertise across the asset lifecycle to help leaders see differently, decide confidently, and move forward with momentum.

That is the foundation of our life sciences consulting services — and the reason clients trust us when the stakes are highest.

Solutions to see differently and decide confidently

We integrate proprietary information platforms, diverse scientific and commercial expertise, analytics, modeling, and strategic intelligence so teams can move faster with rigor.

Model builder

Automate calculations, reduce errors, and collaborate globally to accelerate health economics and outcomes research across the therapy lifecycle. Our Acumetis Model Builder empowers life sciences teams to create accurate, HTA and payer-ready economic models in minutes, supporting pharmaceutical commercial strategy and market access.

Launch Catalyst

Built on 200+ launches and thousands of hours of real-world experience, our launch planning platform generates tailored, actionable plans aligned to your specific product and strategy. Identify risks early, navigate complexity with confidence, and execute with precision; our tool helps you and your team turn abstract planning into practical, high-quality launch execution.

NMA builder

Acumetis NMA Builder lets life sciences teams run complex network meta-analyses quickly, accurately, and without specialized statistical knowledge. With an intuitive interface, validated calculations, and robust reporting, it turns complex data into actionable insights for health economics, pharma commercial strategy, and market access decisions.